Kayne Anderson Rudnick Investment Management LLC Sells 468 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Kayne Anderson Rudnick Investment Management LLC reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,278 shares of the biopharmaceutical company's stock after selling 468 shares during the period. Kayne Anderson Rudnick Investment Management LLC's holdings in Regeneron Pharmaceuticals were worth $3,760,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in REGN. Pamalican Asset Management Ltd acquired a new position in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $4,915,000. Intact Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $356,000. Rhenman & Partners Asset Management AB increased its holdings in shares of Regeneron Pharmaceuticals by 11.4% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock worth $30,956,000 after acquiring an additional 4,457 shares during the period. Principal Financial Group Inc. lifted its position in Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after purchasing an additional 2,828 shares during the last quarter. Finally, Fagan Associates Inc. grew its position in Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after purchasing an additional 3,832 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

REGN has been the subject of several analyst reports. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday. They set an "overweight" rating and a $695.00 price objective for the company. Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Robert W. Baird decreased their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research report on Friday. Bank of America decreased their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a report on Thursday, April 17th. Finally, UBS Group cut Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their price target for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $945.32.

Regeneron Pharmaceuticals Stock Up 0.5 %

Shares of NASDAQ REGN traded up $2.88 during mid-day trading on Friday, reaching $602.64. The company had a trading volume of 964,377 shares, compared to its average volume of 723,191. The stock has a market capitalization of $65.88 billion, a PE ratio of 15.74, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a twelve month low of $525.99 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock's 50 day moving average is $638.93 and its 200-day moving average is $728.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm posted $11.86 earnings per share. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.58%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.